Results 51 to 60 of about 5,456,142 (288)

Inflammation in MASLD progression and cancerKey points:

JHEP Reports
Summary: Steatotic liver diseases include metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease, and metabolic dysfunction and alcohol-related liver disease (MetALD), encompassing a spectrum of metabolic liver
Yeonsoo Kim, Yunseo Park, Hyunsoo Rho, Tiantian Yao, Bin Gao, Seonghwan Hwang   +5 more
doaj   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

MetALD: Clinical aspects, pathophysiology and treatmentKeypoints

JHEP Reports
Summary: Metabolic dysfunction-associated steatotic liver disease (MASLD) and alcohol-related liver disease (ALD) are the most prevalent causes of chronic liver disease worldwide. Both conditions have many pathophysiological mechanisms in common, such as
Jordi Gratacós-Ginès, Silvia Ariño, Pau Sancho-Bru, Ramon Bataller, Elisa Pose   +4 more
doaj   +1 more source

Economic evaluations of antiobesity medications: A systematic literature review

British Journal of Clinical Pharmacology, EarlyView.
The global prevalence of obesity is rising rapidly. With several antiobesity medications approved and many more in development, understanding their economic value is increasingly important. This study reviews full economic evaluations of approved antiobesity medications to assess cost‐effectiveness and inform reimbursement and access decisions.
Martina Jurković, Almir Fajkić, Andrea Katrin Faour, Mirna Momčilović, Petra Turčić, Andrej Belančić   +5 more
wiley   +1 more source

Pharmacokinetics and safety of a modified‐release psilocybin formulation: A SAD Phase I trial in normal‐weight and overweight/obese participants

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to evaluate the safety, tolerability and pharmacokinetics of a novel oral modified‐release psilocybin formulation (REL‐P11) in normal‐weight and overweight/obese healthy adults and to assess its suitability for controlled, subperceptual exposure, in light of emerging evidence supporting serotonergic modulation in metabolic ...
Anna Signor, Stefano Comai, Gianfranco Pasut, Franco Folli, Marco Gentilucci, Negar Gharavi, Sofia Raitsin, Thuy Van Nguyen, Marco Pappagallo, Andrea Mattarei, Paolo L. Manfredi, Sara De Martin   +11 more
wiley   +1 more source

Viability assessment and transplantation of fatty liver grafts using end‐ischemic normothermic machine perfusion

Liver Transplantation, EarlyView., 2022
Abstract End‐ischemic viability testing by normothermic machine perfusion (NMP) represents an effective strategy to recover liver grafts having initially been discarded for liver transplantation (LT). However, its results in the setting of significant (≥30%) macrovesicular steatosis (MaS) have not been specifically assessed.
Damiano Patrono, Riccardo De Carlis, Alessandro Gambella, Francesca Farnesi, Alice Podestà, Andrea Lauterio, Francesco Tandoi, Luciano De Carlis, Renato Romagnoli   +8 more
wiley   +1 more source

A New Korean Nomenclature for Steatotic Liver Disease

The Korean Journal of Gastroenterology
Background/Aims: Necrotizing pancreatitis (NP) presents a more severe clinical trajectory and increased mortality compared to edematous pancreatitis. Prompt identification of NP is vital for patient prognosis. A risk prediction model for NP among Chinese patients has been developed and validated to aid in early detection.
openaire   +8 more sources

Global trends, epidemiological patterns, and disability burden of metabolic dysfunction-associated steatotic liver disease–related cirrhosis from 1990 to 2021: A comprehensive analysis of the Global Burden of Disease study

Journal of International Medical Research
Objectives To assess long-term global trends in the burden of metabolic dysfunction-associated steatotic liver disease–related cirrhosis and develop a simplified, waist circumference–based prediction model for early identification of individuals at risk ...
Xuli Wang, Bingwei Wang
doaj   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source

Metabolic signatures of metabolic dysfunction-associated steatotic liver disease in severely obese patients [PDF]

BackroundMetabolic dysfunction-associated steatotic liver disease (MASLD) can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. Still, most patients with MASLD die from cardiovascular diseases indicating metabolic alterations related to ...
Babu, Ambrin Farizah, Hanhineva, Kati, Käkelä, Pirjo, Kärjä, Vesa, Palomurto, Saana, Männistö, Ville, Lehtonen, Marko, Pihlajamäki, Jussi   +7 more
core   +1 more source